Latest Intelligence in Japan

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

NTT DOCOMO's virtual prepaid card faces usage struggle

NTT DOCOMO's new virtual Visa prepaid card service for online shoppers will require considerable long-term investment to garner any real payoffs, as there is a general unwillingness to use prepaid online in Japan.

Published By Datamonitor
26 Sep 2013
Expert View
Expert View

Abenomics spurring Japanese wealth M&A

Divergent views on Japan are resulting in motivated sellers and willing buyers. Societe Generale has become the latest foreign player to sell out of Japan's wealth management market, but Datamonitor doubts it will be the last.

Published By Datamonitor
26 Jul 2013
Expert View
Expert View

Vehicle recall could prove damaging to Japanese automakers

Up to 3.4 million Japanese-made cars will be recalled worldwide by Toyota, Honda, Mazda, and Nissan over faulty airbags. Toyota is the hardest hit, being poised to recall 1.73 million cars. The firms have declined to reveal the financial cost of the move, but reputational damage - including loss of consumer confidence and sales declines - may be more significant than any monetary loss.

Published By Datamonitor
15 Apr 2013
Expert View
Expert View

Motorists in China respond to Jaguar Land Rover's premium positioning

As a result of increased demand, primarily in the Far East, JLR is set to create 800 new jobs, whereas Honda is due to cut the same number of positions. The latter's new focus on fuel-efficient cars in North America should help it to weather the storm, while JLR ought to stick with its current successful tactics.

Published By Datamonitor
22 Jan 2013
Expert View
Expert View

There is still wealth in Japan

Bank of America Merrill Lynch has become the third international bank to pull out of the Japanese private wealth management market, announcing the sale of its stake in its joint venture with Mitsubishi UFJ. Japan is tough for foreign banks but is still the largest Asian private banking market, with high net worth assets forecast to grow.

Published By Datamonitor
21 Dec 2012
Expert View
Expert View

Johnson & Johnson: Zytiga gains expanded prostate cancer indication in the US

Zytiga's indication expansion for the treatment of pre-chemotherapy castration-resistant metastatic prostate cancer significantly increases its commercial potential. However, potential competition from Xtandi may restrict sales.

Published By Datamonitor
13 Dec 2012
Expert View
Expert View

Pfizer: new data bode well for potential first-in-class CDK inhibitor

Pfizer has announced positive Phase II trial data for its ER+/HER2-negative breast cancer drug PD-991. If the strong efficacy is repeated in the planned Phase III pivotal study, PD-991 is likely to generate considerable revenue in the lucrative first-line advanced and metastatic ER+/HER2-negative breast cancer treatment setting, and is well positioned to become the first-in-class CDK inhibitor.

Published By Datamonitor
07 Dec 2012
Expert View
Expert View

JCB learns from experience with new mobile wallet

The JCB Mobile Wallet will require significant long-term investment to garner any real payoffs - particularly with regards to its features and offers - as nearly half of Japanese consumers currently have a mobile wallet but do not use it.

Published By Datamonitor
16 Nov 2012
Expert View
Expert View

Eisai: novel Fycompa expands treatment options for refractory epilepsy in US

Eisai's Fycompa has become the first AMPA receptor antagonist to gain FDA approval for the adjunctive treatment of partial-onset seizures. While underwhelming clinical trial data, DEA scheduling, and a boxed warning will hinder revenues, Fycompa's novel class, convenient dosing regimen, and preferable side-effect profile will support its uptake in the drug-resistant patient population.

Published By Datamonitor
25 Oct 2012
Expert View
Expert View

Eli Lilly: EXPEDITION is over but solanezumab should live on

While both EXPEDITION studies missed their primary endpoints, a pooled analysis of solanezumab data has revealed a significant reduction in cognitive decline in mild Alzheimer's disease. The drug's commercial potential in this indication should ensure that Lilly conducts further studies, despite the inherent high risk of failure.

Published By Datamonitor
09 Oct 2012

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.